Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention

Expert Review of Molecular Diagnostics

Volumn 17, Issue 4, 2017, Pages 379-391

  Gradíssimo, Ana ^a   Burk, Robert D ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Microbiology & Immunology ^*  (United States)

^c Epidemiology and Population Health   (United States)

Author keywords

Cervical cancer; human papillomavirus; molecular testing; NGS; screening; triage

Indexed keywords

CANCER PREVENTION; GENOTYPE; HUMAN; INFORMATION PROCESSING; NEXT GENERATION SEQUENCING; PREDICTIVE VALUE; PREVALENCE; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; ALPHAPAPILLOMAVIRUS; DEVICES; FEMALE; GENETICS; GENOTYPING TECHNIQUE; MOLECULAR DIAGNOSIS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 85015732726     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2017.1293525     Document Type: Review

References (100)

1. Forman D, De Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
2. Wang J, Aldabagh B, Yu J, et al. Role of human papillomavirus in cutaneous squamous cell carcinoma:a meta-analysis. J Am Acad Dermat. 2014;70(4):621–629.
3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
4. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31(Suppl 7):H1–31.
5. Kesic V., Prevention of cervical cancer in Central and Eastern Europe and Central Asia:a challenge for the future. Vaccine. 2013;31(Suppl 7):vii–ix.
6. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000;36(17):2209–2214.
7. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening:joint European cohort study. BMJ. 2008;337:a1754.
8. Bosch FX, Robles C, Diaz M, et al. HPV-FASTER:broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;133(2):119–132.•• This paper describes an approach for cervical cancer prevention utilizing combined vaccination and screening, as a new paradigm.
9. Ogilvie GS, Krajden M, Van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL):complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440–448.
10. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer:follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–532.
11. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3:a retrospective cohort study. Lancet Oncol. 2008;9(5):425–434.• This was a study that followed women with CIN3 of whom 31–50% not adequately treated went on to develop invasive cancer, providing an estimate of the risk of progression.
12. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.•• This is an expansive review of the biology and epidemiology of oncogenic HPV in the human population.
13. Cuzick J. Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol. 2010;117(2 Suppl):S11–14.
14. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening:interim clinical guidance. Gynecol Oncol. 2015;136(2):178–182.• This guideline discusses the use of HPV DNA testing for prevention of cervical cancer in a screening program.
15. Abreu AL, Souza RP, Gimenes F, et al. A review of methods for detect human Papillomavirus infection. Virol J. 2012;9:262.
16. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples:a meta-analysis. Lancet Oncol. 2014;15(2):172–183.
17. Group NHSI, Kelly RS, Patnick J, Kitchener HC, et al. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology:results from the Sentinel Sites study. Br J Cancer. 2011;105(7):983–988.
18. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172.
19. Lorincz A, Castanon A, Wey Lim AW, et al. New strategies for human papillomavirus-based cervical screening. Womens Health (Lond). 2013;9(5):443–452.
20. Castanon A, Landy R, Sasieni P. By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England? J Med Screen. 2016. DOI:10.1177/096914136654197
21. Rijkaart DC, Berkhof J, Van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130(3):602–610.
22. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus:end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–197.
23. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–428.
24. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology:a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–672.
25. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening:extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–871.
26. Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(Suppl 1):S49–55.• This review gives an update on the triage of women identified with an HPV infection with and without cytological abnormalities.
27. Arbyn M, Ronco G, Cuzick J, et al. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer. 2009;125(11):2489–2496.
28. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99.
29. Levi AW, Bernstein JI, Hui P, et al. A comparison of the Roche Cobas HPV test with the Hybrid Capture 2 test for the detection of high-risk human papillomavirus genotypes. Arch Pathol Lab Med. 2016;140(2):153–157.
30. Mesher D, Szarewski A, Cadman L, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing:results from the HART study. Br J Cancer. 2010;102(9):1405–1410.
31. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88–99.
32. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen. 2002;9(2):49–51.
33. Harari A, Chen Z, Burk RD. Human papillomavirus genomics:past, present and future. Curr Probl Dermatol. 2014;45:1–18.
34. Conway C, Chalkley R, High A, et al. Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn. 2012;14(2):104–111.
35. Snijders PJ, Van Den Brule AJ, Schrijnemakers HF, et al. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990;71(Pt 1):173–181.
36. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus:comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997;35(6):1304–1310.
37. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990;82(18):1477–1484.
38. De Roda Husman AM, Walboomers JM, Van Den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3ʹ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76(Pt 4):1057–1062.
39. Castle PE, Porras C, Quint WG, et al. Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol. 2008;46(10):3437–3445.
40. Koskinen WJ, Brondbo K, Mellin Dahlstrand H, et al. Alcohol, smoking and human papillomavirus in laryngeal carcinoma:a Nordic prospective multicenter study. J Cancer Res Clin Oncol. 2007;133(9):673–678.
41. Tjalma WA, Depuydt CE. Cervical cancer screening:which HPV test should be used–L1 or E6/E7? Eur J Obstet Gynecol Reprod Biol. 2013;170(1):45–46.
42. Kerr DA, Sweeney B, Arpin RN, 3rd, et al. Automated extraction of formalin-fixed, paraffin-embedded tissue for high-risk human papillomavirus testing of head and neck squamous cell carcinomas using the Roche Cobas 4800 system. Arch Pathol Lab Med. 2016;140(8):844–848.
43. Depuydt CE, Boulet GA, Horvath CA, et al. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med. 2007;11(4):881–891.
44. Mirabello L, Yeager M, Cullen M, et al. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J Natl Cancer Inst. 2016;108:9.
45. Jelen MM, Chen Z, Kocjan BJ, et al. Global genomic diversity of human papillomavirus 11 based on 433 isolates and 78 complete genome sequences. J Virol. 2016;90(11):5503–5513.
46. Agalliu I, Gapstur S, Chen Z, et al. Associations of oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident head and neck cancer. JAMA Oncol. 2016;2(5):599-606.•• This is the first paper to utilize next-generation sequencing with barcoded primers to characterize the gamut of alpha-, beta- and gamma-HPVs.
47. Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2125–2137.
48. Cuschieri K, Bhatia R, Cruickshank M, et al. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol. 2016;76(Suppl 1):S56–61.
49. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–520.
50. Pista A, Verdasca N, Oliveira A. Clinical performance of the CLART human papillomavirus 2 assay compared with the Hybrid Capture 2 test. J Med Virol. 2011;83(2):272–276.
51. Park Y, Lee E, Choi J, et al. Comparison of the Abbott realtime high-risk human papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J Clin Microbiol. 2012;50(7):2359–2365.
52. Cuschieri K, Cubie H, Graham C, et al. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting:influence of assay target, cut off and age. J Clin Virol. 2014;59(2):104–108.
53. Basu P, Banerjee D, Mittal S, et al. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. J Med Virol. 2016;88(7):1271–1278.
54. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–79.
55. Arroyo LS, Smelov V, Bzhalava D, et al. Next generation sequencing for human papillomavirus genotyping. J Clin Virol. 2013;58(2):437–442.
56. Ekstrom J, Bzhalava D, Svenback D, et al. High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. Int J Cancer. 2011;129(11):2643–2650.
57. Hamady M, Walker JJ, Harris JK, et al. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods. 2008;5(3):235–237.
58. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1–2):232–243.
59. Holmes A, Lameiras S, Jeannot E, et al. Mechanistic signatures of HPV insertions in cervical carcinomas. Npj Genomic Medicine. 2016;1:16004. DOI:10.1038/npjgenmed.2016.4
60. Leeson SC, Alibegashvili T, Arbyn M, et al. HPV testing and vaccination in Europe. J Low Genit Tract Dis. 2014;18(1):61–69.
61. Pedersen K, Sorbye SW, Kristiansen IS, et al. Using novel biomarkers to triage young adult women with minor cervical lesions:a cost-effectiveness analysis. BJOG. 2017;124(3):474–484.
62. Oliveira A, Verdasca N, Pista A. Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia. J Med Virol. 2013;85(7):1235–1241.
63. Iftner T, Becker S, Neis KJ, et al. Head-to-head comparison of the RNA-based Aptima Human Papillomavirus (HPV) assay and the DNA-based Hybrid Capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;53(8):2509–2516.
64. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007;121(12):2787–2793.
65. Wu Z, Qin Y, Yu L, et al. Association between human papillomavirus (HPV) 16, HPV18, and other HR-HPV viral load and the histological classification of cervical lesions:results from a large-scale cross-sectional study. J Med Virol. 2017;89(3):535–541.
66. Bodelon C, Vinokurova S, Sampson JN, et al. Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis. 2016;37(2):188–196.
67. Liu Y, Lu Z, Xu R, et al. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. Oncotarget. 2016;7(5):5852–5864.•• This paper describes the use of capturing HPV sequencing and next-generation sequencing to identify and map HPV-cellular chimeric sequences.
68. Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999;59(24):6132–6136.
69. Melsheimer P, Vinokurova S, Wentzensen N, et al. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res. 2004;10(9):3059–3063.
70. Thorland EC, Myers SL, Gostout BS, et al. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene. 2003;22(8):1225–1237.
71. Luft F, Klaes R, Nees M, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer. 2001;92(1):9–17.
72. Gradíssimo Oliveira ADC, Verdasca N, Pista A. Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia. Clin Microbiol Infect. 2013;19(10):447–450.
73. Lorincz AT. The promise and the problems of epigenetics biomarkers in cancer. Expert Opin Med Diagn. 2011;5(5):375–379.
74. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371–375.
75. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
76. Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res. 2009-2019;21(9):2015.
77. Cancer Genome Atlas Research N. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017; 10.1038/nature21386.•• This paper is the most definitive description of the molecular characterization of cervical cancer providing information on differences between squamous, glandular, and other forms of cervix cancer.
78. Brandsma JL, Sun Y, Lizardi PM, et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology. 2009;389(1–2):100–107.
79. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer. 2013;132(6):1412–1422.
80. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138(11):2745–2751.
81. Wijetunga NA, Belbin TJ, Burk RD, et al. Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia. Gynecol Oncol. 2016;142(3):566–573.
82. Lorincz A, Raison C. Scratching the surface of tomorrow’s diagnostics:the Editor-in-Chief’s opinion at the 15th year of Expert Review of Molecular Diagnostics. Expert Rev Mol Diagn. 2015;15(1):5–8.
83. Mirabello L, Frimer M, Harari A, et al. HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer. 2015;136(4):E146–153.
84. Shen-Gunther J, Wang CM, Poage GM, et al. Molecular Pap smear:HPV genotype and DNA methylation of ADCY8, CDH8, and ZNF582 as an integrated biomarker for high-grade cervical cytology. Clin Epigenetics. 2016;8:96.
85. Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection:appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–299.
86. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–1159.
87. Guerrero-Preston R, Valle BL, Jedlicka A, et al. Molecular triage of premalignant lesions in liquid-based cervical cytology and circulating cell-free DNA from urine, using a panel of methylated human papilloma virus and host genes. Cancer Prev Res (Phila). 2016;9(12):915–924.
88. Wentzensen N, Sun C, Ghosh A, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst. 2012;104(22):1738–1749.
89. Kalantari M, Osann K, Calleja-Macias IE, et al. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene:considerations for use as biomarkers of the progression of cervical neoplasia. Virology. 2014;448:314–321.
90. Marongiu L, Godi A, Parry JV, et al. Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer. 2014;14:384.
91. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers:implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
92. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–2008.
93. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine:combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015;16(7):775–786.
94. Lowy DR. HPV vaccination to prevent cervical cancer and other HPV-associated disease:from basic science to effective interventions. J Clin Invest. 2016;126(1):5–11.
95. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
96. Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140.
97. Kim J, Bell C, Sun M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281–288.
98. Chesson HW, Flagg EW, Koutsky L, et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine. 2013;31(29):3019–3024.
99. Malik T, Reimer J, Gumel A, et al. The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer. Math Biosci Eng. 2013;10(4):1173–1205.
100. Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer:ASCO resource-stratified clinical practice guideline. J Global Oncol. 2016. DOI:10.1200/JGO.2016.006577